FEMY - Femasys Inc. Stock Price, Fair Value and News

1.28USD-0.04 (-3.03%)Delayed as of 22 Apr 2024, 11:48 am ET

Market Summary

USD1.28-0.04

Delayedas of 22 Apr 2024, 11:48 am

-3.03%

FEMY Stock Price

View Fullscreen

FEMY RSI Chart

FEMY Valuation

Market Cap

29.2M

Price/Earnings (Trailing)

-2.05

Price/Sales (Trailing)

27.21

EV/EBITDA

-0.55

Price/Free Cashflow

-2.55

FEMY Price/Sales (Trailing)

FEMY Profitability

EBT Margin

-1328.66%

Return on Equity

-77.63%

Return on Assets

-51.33%

Free Cashflow Yield

-39.16%

FEMY Fundamentals

FEMY Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-9.02%

Rev. Growth (Qtr)

-12.79%

FEMY Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

-52.39%

Earnings Growth (Qtr)

-10.35%

Breaking Down FEMY Revenue

52 Week Range

0.254.75

(Low)(High)

Last 7 days

2.3%

Last 30 days

-26.1%

Last 90 days

66.3%

Trailing 12 Months

54.6%

How does FEMY drawdown profile look like?

FEMY Financial Health

Current Ratio

7.59

FEMY Investor Care

Shares Dilution (1Y)

86.14%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.2M	1.2M	1.1M	1.1M
2022	1.2M	1.1M	1.2M	1.2M
2021	1.1M	1.1M	1.1M	1.2M
2020	0	0	0	1.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Femasys Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2021	dyett john	acquired	-	-	175,635	-
Dec 15, 2021	dyett john	sold	-	-	-3,219,800	-
Dec 15, 2021	witte william benson	acquired	-	-	12,191	-
Jun 23, 2021	dyett john	bought	9,950	9.95	1,000	-
Jun 22, 2021	dyett john	acquired	-	-	3,219,790	-
Jun 22, 2021	dyett john	bought	520,000	13.00	40,000	-
Jun 22, 2021	dyett john	acquired	-	-	63,709	-
Jun 22, 2021	adams john q jr	acquired	-	-	199,938	-
Jun 22, 2021	adams john q jr	bought	520,000	13.00	40,000	-
Jun 22, 2021	uzialko edward r	bought	1,300,000	13.00	100,000	-

Which funds bought or sold FEMY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	77.19	-109,738	151,379	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	new	-	975	975	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-295,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-135,849	-	-%
Feb 14, 2024	CLEAR STREET LLC	sold off	-100	-745,000	-	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-0.19	-106,000	52,000	-%
Feb 14, 2024	Mariner, LLC	unchanged	-	-37,569	18,270	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	11,596	11,596	-%
Feb 14, 2024	Creative Planning	unchanged	-	-21,104	10,263	-%
Feb 14, 2024	Schonfeld Strategic Advisors LLC	sold off	-100	-199,064	-	-%

Are Funds Buying or Selling FEMY?

Are funds buying FEMY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FEMY

No. of Funds

Unveiling Femasys Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 22, 2023	pharmacyte biotech, inc.	37.0%	12,711,864	SC 13D

Recent SEC filings of Femasys Inc.

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	S-8	Employee Benefits Plan
Apr 05, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 20, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Feb 28, 2024	8-K	Current Report
Feb 13, 2024	4	Insider Trading
Feb 13, 2024	3	Insider Trading
Feb 06, 2024	8-K	Current Report

Peers (Alternatives to Femasys Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Femasys Inc. News

Latest updates

Femasys Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-12.8%	213,111	244,361	320,514	293,984	234,244	347,456	303,113	321,405	254,327	269,581	326,006	329,775	321,492	313,208	183,234
Gross Profit	-100.0%	-	158,175	210,045	188,864	148,785	216,005	200,760	198,730	190,015	164,178	218,379	236,733	-	222,773	127,959
Operating Expenses	8.1%	4,584,332	4,239,439	3,146,007	3,230,538	3,149,147	3,273,194	2,860,723	3,081,480	2,547,751	2,415,623	2,119,454	2,063,281	-	1,787,650	1,611,592
S&GA Expenses	189.8%	205,448	70,883	128,899	244,896	336,438	90,374	63,177	68,863	120,804	43,284	21,828	22,819	-	31,010	13,384
R&D Expenses	-0.1%	2,071,260	2,072,830	1,527,172	1,537,439	1,271,608	1,648,160	1,472,924	1,421,063	1,053,837	1,140,577	894,868	995,022	-	995,620	888,701
EBITDA Margin	-27.8%	-12.68	-9.92	-9.06	-9.18	-8.96	-5.67	-6.05	-5.92	-5.87	-5.44	-5.61	-5.80	-5.99	-	-
Interest Expenses	1835.6%	155,487	8,033	198	1,672	3,842	6,005	883	2,734	4,680	7,055	3,643	3,848	-	3,760	3,438
Income Taxes	-104.7%	-212	4,550	-	-	1,250	4,250	-	800	3,600	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-2,360,853	-2,259,701	-1,083,059	-	-	-1,568,295	-1,485,451
EBT Margin	-27.5%	-13.29	-10.42	-9.52	-9.66	-9.44	-6.14	-6.56	-6.43	-6.39	-6.04	-6.23	-6.44	-6.66	-	-
Net Income	-10.3%	-4,410,454	-3,996,905	-2,893,508	-2,946,257	-2,894,196	-2,982,843	-2,634,101	-2,883,030	-2,364,853	-2,259,701	-1,083,059	-1,830,232	-	-1,568,295	-1,485,451
Net Income Margin	-14.1%	-13.29	-11.65	-9.80	-9.72	-9.45	-8.86	-8.83	-7.33	-6.39	-6.04	-6.24	-6.44	-6.66	-	-
Free Cashflow	-6.9%	-3,080,879	-2,882,911	-2,804,135	-2,656,538	-2,961,764	-2,748,730	-2,554,565	-2,874,389	-2,366,525	-1,977,235	-2,733,211	-1,160,682	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	86.9%	28.00	15.00	14.00	14.00	17.00	20.00	23.00	26.00	29.00	31.00	34.00	8.00
Current Assets	126.7%	23.00	10.00	12.00	11.00	14.00	17.00	20.00	23.00	26.00	28.00	31.00	4.00
Cash Equivalents	149.8%	22.00	9.00	11.00	10.00	13.00	16.00	19.00	22.00	25.00	27.00	30.00	3.00
Inventory	10.7%	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	-4.3%	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	113.2%	9.00	4.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	4.00
Current Liabilities	39.6%	3.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Shareholder's Equity	75.7%	18.00	10.00	13.00	12.00	15.00	18.00	21.00	23.00	26.00	29.00	31.00	-
Retained Earnings	-4.2%	-108	-103	-99.97	-97.08	-94.13	-91.24	-88.26	-85.62	-82.74	-80.38	-78.12	-75.20
Additional Paid-In Capital	9.8%	124	113	111	109	109	109	109	108	108	108	108	23.00
Accumulated Depreciation	-1.4%	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Shares Outstanding	35.4%	22.00	16.00	15.00	12.00	12.00	12.00	12.00	12.00	12.00	5.00	2.00	1.00
Float	-	-	-	7.00	-	-	-	23.00	-	-	-	53.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-6.3%	-3,035	-2,855	-2,741	-2,647	-2,867	-2,730	-2,379	-2,754	-2,247	-1,801	-2,720	-1,160	-	-	-
Share Based Compensation	-90.3%	49.00	504	65.00	57.00	67.00	52.00	62.00	44.00	29.00	33.00	58.00	72.00	-	-	-
Cashflow From Investing	-65.3%	-44.90	-27.17	-62.95	-8.90	-93.88	-18.54	-174	-120	-118	-175	-12.51	-	-	-	-
Cashflow From Financing	1750.4%	16,105	870	3,348	-144	-81.95	-362	-96.65	-141	-130	-601	30,576	-144	-	-	-

FEMY Income Statement

2023-12-31

Statements of Comprehensive Loss - USD ($)	12 Months Ended
Statements of Comprehensive Loss - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Statements of Comprehensive Loss [Abstract]
Sales	$ 1,071,970	$ 1,206,218
Cost of sales (excluding depreciation expense)	380,069	441,938
Operating expenses:
Research and development	7,208,701	5,813,755
Sales and marketing	650,126	558,852
General and administrative	6,858,008	5,430,704
Depreciation and amortization	483,481	561,233
Total operating expenses	15,200,316	12,364,544
Loss from operations	(14,508,415)	(11,600,264)
Other income (expense):
Interest income	431,019	228,164
Interest expense	(165,390)	(13,464)
Other expense	0	(2,306)
Total other income	265,629	212,394
Loss before income taxes	(14,242,786)	(11,387,870)
Income tax expense	4,338	6,300
Net loss	(14,247,124)	(11,394,170)
Net loss attributable to common stockholders, basic	(14,247,124)	(11,394,170)
Net loss attributable to common stockholders, diluted	$ (14,247,124)	$ (11,394,170)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.93)	$ (0.96)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.93)	$ (0.96)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	15,384,376	11,815,019
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	15,384,376	11,815,019

FEMY Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,716,077	$ 12,961,936
Accounts receivable, net	98,906	77,470
Inventory, net	667,118	436,723
Prepaid and other current assets	695,879	655,362
Total current assets	23,177,980	14,131,491
Property and equipment, at cost:
Leasehold improvements	1,212,417	1,195,637
Office equipment	47,308	99,344
Furniture and fixtures	414,303	419,303
Machinery and equipment	2,559,356	2,572,243
Construction in progress	423,077	413,843
Property and equipment, gross	4,656,461	4,700,370
Less accumulated depreciation	(3,545,422)	(3,217,319)
Net property and equipment	1,111,039	1,483,051
Long-term assets:
Lease right-of-use assets, net	2,380,225	319,557
Intangible assets, net of accumulated amortization	0	3,294
Other long-term assets	1,086,581	958,177
Total long-term assets	3,466,806	1,281,028
Total assets	27,755,825	16,895,570
Current liabilities:
Accounts payable	1,137,823	510,758
Accrued expenses	1,444,296	456,714
Note payable	0	141,298
Clinical holdback - current portion	65,300	45,206
Lease liabilities - current portion	406,636	373,833
Total current liabilities	3,054,055	1,527,809
Long-term liabilities:
Clinical holdback - long-term portion	54,935	96,658
Convertible Notes Payable, net (including related parties)	4,258,179	0
Lease liabilities - long-term portion	2,036,067	28,584
Total long-term liabilities	6,349,181	125,242
Total liabilities	9,403,236	1,653,051
Commitments and contingencies
Stockholders' equity:
Common stock, $.001 par, 200,000,000 authorized, 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023; and 11,986,927 shares issued and 11,869,704 outstanding as of December 31, 2022	21,775	11,987
Treasury stock, 117,223 common shares	(60,000)	(60,000)
Warrants	2,787,137	567,972
Additional paid-in-capital	123,985,306	108,857,065
Accumulated deficit	(108,381,629)	(94,134,505)
Total stockholders' equity	18,352,589	15,242,519
Total liabilities and stockholders' equity	$ 27,755,825	$ 16,895,570

About Femasys Inc.

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

CEO	Ms. Kathy Lee-Sepsick
WEBSITE	femasys.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	34

Femasys Inc. Frequently Asked Questions

What is the ticker symbol for Femasys Inc.? What does FEMY stand for in stocks?

FEMY is the stock ticker symbol of Femasys Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Femasys Inc. (FEMY)?

As of Fri Apr 19 2024, market cap of Femasys Inc. is 29.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FEMY stock?

You can check FEMY's fair value in chart for subscribers.

What is the fair value of FEMY stock?

You can check FEMY's fair value in chart for subscribers. The fair value of Femasys Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Femasys Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FEMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Femasys Inc. a good stock to buy?

The fair value guage provides a quick view whether FEMY is over valued or under valued. Whether Femasys Inc. is cheap or expensive depends on the assumptions which impact Femasys Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FEMY.

What is Femasys Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, FEMY's PE ratio (Price to Earnings) is -2.05 and Price to Sales (PS) ratio is 27.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FEMY PE ratio will change depending on the future growth rate expectations of investors.